During a congressional hearing, Mylan CEO Heather Bresch faced questions from heated lawmakers concerning her company's huge profits and even her mother's actions, according to The Hill.
Here are five insights:
1. Legislators pressed Ms. Bresch on her $18 million salary, despite the executive trying to speak about Mylan's efforts to offer Epic generics. When Ms. Bresch said Mylan's profits are falling, House Oversight Committee Chairman Jason Chaffetz (R-Utah) said, "This is why we don't believe you." He said the profits Mylan accrued from its $300 generic actually surpassed the profits it made from its $608 version on the drug.
2. In response to Rep. Chaffetz's claims, Ms. Bresch retorted the company does not make $600 off of their $608 drug. Rather, she said the company only received $200, to which Mr. Chaffetz again reaffirmed his disbelief. He said, "Your numbers don't work based on the documents you've given us."
3. Rep. Tammy Duckworth (D-Ill.) claimed Ms. Bresch's mother used her position on a school board to bolster EpiPen's sales. Rep. Duckworth accused her mother of "lobbying to make sure they're in your schools," according to The Hill.
4. Ms. Bresch denied her mother would encourage lawmakers to push EpiPen into schools, calling the claim a "very cheap shot."
5. The Hill reports when Ms. Bresch's mother, Gayle Manchin, was president of the National Association of State Boards of Education, Mylan launched its epinephrine policy initiative. The initiative promoted access to epinephrine auto-injectors in schools and gave more than 700,000 free devices to schools across the Untied States. On Sept. 20, Mylan said the initiative grew due to a "complete lack of awareness and access to this product."
More articles on practice management:
AAOS CEO Karen Hackett to retire April 2017: 3 things to know
SC Supreme Court overturns ban on physician-employed physical therapists: 3 notes
Hospital employment not correlated with improving care: 4 highlights